RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement From Broadfin Capital LLC
31 déc. 2013 09h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Dec. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
Qu Biologics Begins Research with McMaster University to Study New Crohn's Disease Research Model
03 déc. 2013 10h00 HE
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to stimulate the...
Qu Biologics Welcomes Dr. Richard Fedorak and Dr. William Sandborn to Newly Formed IBD Advisory Team for Crohn's Disease Clinical Trial
30 mai 2013 13h43 HE
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...